The virulent microorganisms that we try to contain with new antimicrobial agents quickly find the gap in our defenses and exploit it. Resistance to all available antibiotics at the same time, however, rarely occurs. The authors report the most current antimicrobials used as monotherapy or in combination to successfully treat the more resistant pathogens. The higher mortality and subsequent cost to treat these infections are reviewed.